Spin-off News
Here you find a selection of press releases from Max Planck Innovation spin-offs.
14.02.2012
SuppreMol releases positive interim Phase Ib/IIa results on SM101 in Primary Immune Thrombocytopenia (ITP) trials. More
08.12.2011
MorphoSys to Receive Milestone Payment for CNTO 1959 Phase 2 Program. More
07.12.2011
Protagen expands Cooperation with Bayer HealthCare. More
06.12.2011
SCIENION founds US subsidiary SCIENION US, Inc. - Expansion in the North American market planned. More
29.11.2011
Alnylam Completes Enrollment in Phase IIb Study of ALN-RSV01, an RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection. More
28.11.2011
SuppreMol starts SM101 dosing in the context of SMILE study (SM101 In Lupus Erythematosus). More
17.11.2011
Cenix signs RNAi research agreement with SYGNIS. More
27.10.2011
Taconic (formerly ARTEMIS) and Oncodesign Announce Agreement to Co-Promote and Co-Develop Solutions to Advance Oncology Research. More
27.10.2011
Evotec achieves two Milestones in Fragment-based Drug Discovery Alliance with Shionogi. More
25.10.2011
Epigenomics announces the European launch of Epi proColon® 2.0 CE. More
11.10.2011
Agennix (formerly GPC) Announces Data from Talactoferrin Phase II Trial in Non-Small Cell Lung Cancer Published in Journal of Clinical Oncology. More
10.10.2011
Biometra expands TProfessional Thermocycler Productline with New Model. More
05.10.2011
Evotec enters into a second multi year, multi target integrated drug discovery collaboration with UCB in the field of immunology. More
26.09.2011
Alnylam Initiates Phase I Clinical Study of ALN-PCS, an RNAi Therapeutic Targeting PCSK9 for the Treatment of Severe Hypercholesterolemia. More
19.09.2011
Epigenomics AG reports Epi proColon® 2.0 finds 95% of cancers in clinical study. More
14.09.2011
MorphoSys Announces Clinical Milestone in Cancer Antibody Program with Bayer HealthCare Pharmaceuticals. More
02.08.2011
SuppreMol employs Protagen biomarkers in SLE-study. More
30.06.2011
Agennix Initiates Phase II/III OASIS Trial with Talactoferrin in Severe Sepsis. More
28.06.2011
Ruhr Consortium, amongst them Lead Discovery Center GmbH, receives 3.6 Mio. Euro funding for the development of drugs against cancer and metabolic diseases. More
28.06.2011
AMRI and Proteros Biostructures GmbH Announce Strategic Alliance. More
27.06.2011
R-Biopharm to use SCIENIONs sciFLEXARRAYER for the production of novel chips designed to detect antibiotics in milk - Novel milkchip for better consumer protection. More
27.06.2011
Evotec AG today announced the achievement of a milestone in an ion channel research collaboration with Ono Pharmaceutical Co., Ltd. (Ono). More
24.06.2011
Evotec and Roche to jointly develop biomarkers in oncology. More
08.06.2011
Affectis Pharmaceuticals and Merck Serono Announce an Agreement to Develop Oral Drugs for Neurodegenerative Diseases. More
04.06.2011
Alnylam Presents Phase I Data for ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancers, at American Society of Clinical Oncology (ASCO) Meeting. More
01.06.2011
Anadys Announces Issuance of U.S. Patent Covering Setrobuvir (ANA598). More
31.05.2011
Evotec receives milestone payment from Boehringer Ingelheim as phase I clinical trial in pain starts. More
17.05.2011
SuppreMol obtains option to in-license antibody against interleukin 3 (IL-3) from the Bayerische Patentallianz GmbH. More
16.05.2011
Biometra launches new product "BDA live compact". More
10.05.2011
A Forward Move to the Far East: Another Patent is Now Granted to Capsulution LBL Technology in Japan. More
06.05.2011
Epigenomics AG: Life Technologies to Supply Crucial Components for Second-Generation Colorectal Cancer Blood Test. More
04.05.2011
Cenix BioScience Signs Collaboration and Technology License Agreement for In Vivo siRNA Delivery. More
29.04.2011
MorphoSys reaches second clinical milestone with OncoMed Pharmaceuticals. More
19.04.2011
Protagen counts on Scienion Technology – Scienion AG today announced that the company will produce protein microarray batches for clinical validation studies of proprietary biomarker panels of Protagen AG. The batch sizes will comprise more than 1000 arrays. Additionally, both companies plan to jointly evaluate new platforms for multiplex analytics and to co-develop novel approaches up to proof-of-concept levels under a strategic partnership. More
29.03.2011
Protagen to Apply UNIarray® Platform for Biogen Idec. More
18.03.2011
Epigenomics AG: Partner Quest Diagnostics Septin9 Test ColoVantage Approved by New York State. More
16.03.2011
MorphoSys Signs Manufacturing Agreement with Boehringer Ingelheim. More
16.03.2011
Agennix AG Announces Completion of Enrollment in Talactoferrin Phase III FORTIS-M Trial in Non-Small Cell Lung Cancer. More
15.03.2011
Alnylam Pharmaceuticals Reaches Settlement in Litigation Regarding Tuschl Patents. More
28.02.2011
Epigenomics and QIAGEN Sign Collaboration Agreement in Colorectal Cancer Blood Testing. More
15.02.2011
Evotec to Strengthen its Compound Collection through a Collaboration with ChemBridge. More
24.01.2011
SuppreMol Completes Successful Pre-IND Meeting with FDA. More
24.01.2011
SuppreMol Completes Successful Pre-IND Meeting with FDA. More
12.01.2011
Cenix BioScience grows, establishing new R&D subsidiary in Flanders, Belgium. More
04.01.2011
Anadys Pharmaceuticals Initiates Phase IIb Study of ANA598 in HCV Patients. More
04.01.2011
Alnylam Demonstrates RNAi in Man with Systemically Delivered RNAi Therapeutics. More
News alert
Do you want to receive our newsletter and press releases?
Subscribe here
Media contact
Markus Berninger
Phone: (089) 290919-30